Thu 20 Aug 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| "A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Stroke and Death in Patients with Acute Ischaemic Stroke or Transient Ischaemic Attack[THALES - Acute STroke or Transient IscHaemic Attack Treated with TicAgreLor and ASA for PrEvention of Stroke and Death]" | AstraZeneca | Ongoing | Ticagrelor | 3 | D5134C00003 | King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah) |
| Follow-up of Phase I/II study of CaspaCIDe T cells (BPX-501) from an HLA-partially matched family donor after negative selection of TCR αβ+T cells in pediatric patients affected by hematological disorders | Bellicum Pharmaceuticals | Ongoing | Rimiducid | 2 | CT17-008-R | King Abdulaziz Medical City NG (Riyadh) |
| A phase 3, multi-center, open-label, randomized study of oral ABL001 versus bosutinib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors | Novartis | Ongoing | ABL001 | 3 | CABL001A2301 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| An observational disease and clinical outcomes registry of patients with acid lipase (LAL) deficiency | Alexion Pharma International Sàrl. | Ongoing | Kanuma | 4 | ALX-LALD-5 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Angiotec tablets (20 mg enalapril) Produced by JPM / Jordan versus Renitec® tablets (20 mg enalapril) Produced by Merck Sharp & Dohme / UK, in healthy subjects under fasting condition. | SFDA | Ongoing | Angiotec | BE | Jun-17 | Saudi Ajal |
| Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Capocard tablets (25 mg captopril) Produced by Dar AlDawa / Jordan versus Capoten® tablets (25 mg captopril) Produced by SPIMACO / KSA, in healthy subjects under fasting condition. | SFDA | Ongoing | Capocard | BE | Jul-17 | Saudi Ajal |
| Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Arena film-coated tablets (150 mg irbesartan) Produced by Jamjoom/ KSA versus Aprovel® film-coated tablets (150 mg irbesartan) Produced by Sanofi-aventis / Germany, in healthy subjects under fasting condition. | SFDA | Ongoing | Arena | BE | Aug-17 | Saudi Ajal |
| Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Biscor film-coated tablets (10 mg bisoprolol fumarate) Produced by Pharma International / Jordan versus Concor® film-coated tablets (10 mg bisoprolol fumarate) Produced by Merck / Germany, in healthy subjects under fasting condition. | SFDA | Ongoing | Biscor | BE | Sep-17 | Saudi Ajal |
| Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Pedovex film-coated tablets (75 mg clopidogrel) Produced by Tabuk / KSA versus Plavix® film-coated tablets (75 mg clopidogrel) Produced by Sanofi-aventis / KSA, in healthy subjects under fasting condition. | SFDA | Ongoing | Pedovex | BE | Oct-17 | Saudi Ajal |
| Randomized, three-way, three-period, single oral dose, open-label, crossover, bioequivalence study to compare Lipomax tablets (20 mg atorvastatin) Produced by SAJA / KSA, versus Lipitor® tablets (20 mg atorvastatin) Produced by Pfizer / Ireland, in healthy subjects under fasting conditions. | SFDA | Ongoing | Lipomax | BE | Nov-17 | Saudi Ajal |
Last update date: 08/05/2025 at 03:17 PM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.